The AVATAR Group, founded in 2007 by Professor Claire Rickard, is a leading independent research organization dedicated to advancing the science of vascular access. Renowned for its rigorous and credible research, AVATAR specializes in a wide range of vascular access devices and patient settings.
Our Research
AVATAR conducts an extensive program of clinical trials, laboratory studies, systematic reviews, and knowledge translation research, including health economics. Our work spans both national and international contexts, aiming to improve patient outcomes and healthcare practices.
Currently, we are engaged in several high-profile trials funded by the Australian National Health and Medical Research Council (NHMRC):
1. PISCES Trial: Peripherally Inserted Central Catheter Securement.
2. e-Vascular Access Passport: Enhancing the experience and outcomes of pediatric central venous access devices.
3. PICNIC Trial: Peripherally Inserted Central Catheter Innovation to Reduce Infections and Clots.
4. DART3: Difficult Access Requires Thought, Training, and Technology.
Our Collaborations
Based at Griffith University in Brisbane and the Gold Coast, Australia, AVATAR collaborates with numerous esteemed institutions such as the University of Queensland, Queensland University of Technology, and the University of the Sunshine Coast. We also partner with various healthcare organizations and professional groups both within Australia and internationally.
Our Mission
No patient or caregiver should endure the pain and complications associated with vascular access devices, such as blockages, dislodgements, infections, or blood clots. At AVATAR, we are committed to ensuring these complications become a thing of the past.
Our mission is to make vascular access complications history.
Join us in our mission to make a difference in vascular access care.
